INDP

Indaptus Therapeutics Inc

INDP, USA

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

https://indaptusrx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INDP
stock
INDP

Published on: 2025-12-12 08:39:47 moha.gov.vn

Read more →
INDP
stock
INDP

Indaptus Therapeutics (NASDAQ:INDP) Downgraded by Wall Street Zen to “Sell” Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.54

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-64.60 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-43.50 %

Low 2%

High 10%

Debt to Equity

-

High

0.49

Low 1

High 0.3

Investors

* Institutions hold a combined 0.47% of the total shares of Indaptus Therapeutics Inc

1.

Fidelity Extended Market Index

(0.2143%)

since

2025/07/31

3.

Fidelity Series Total Market Index

(0.0457%)

since

2025/07/31

4.

Fidelity Total Market Index

(0.0418%)

since

2025/07/31

5.

NT Ext Equity Mkt Idx Fd - NL

(0.0193%)

since

2025/06/30

6.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.015%)

since

2025/06/30

7.

SBI Securities Co Ltd

(0.0141%)

since

2025/06/30

8.

Spartan Total Market Index Pool G

(0.0124%)

since

2025/07/31

9.

Northern Trust Extended Eq Market Idx

(0.0116%)

since

2025/06/30

10.

NT Ext Equity Mkt Idx Fd - L

(0.0116%)

since

2025/06/30

11.

Tower Research Capital LLC

(0.0098%)

since

2025/06/30

12.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0033%)

since

2025/06/30

13.

Bank of America Corp

(0.0028%)

since

2025/06/30

14.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0028%)

since

2024/12/31

15.

Spartan Extended Market Index Pool F

(0.0015%)

since

2025/07/31

16.

FMR Inc

(0.0009%)

since

2025/06/30

17.

Wells Fargo & Co

(0.0002%)

since

2025/06/30

18.

State Street Corp

(0%)

since

2025/06/30

20.

Bangor Savings Bank

(0%)

since

2025/06/30

21.

UBS Group AG

(0%)

since

2025/06/30

22.

Group One Trading, LP

(0%)

since

2025/06/30

23.

Renaissance Technologies Corp

(0%)

since

2025/06/30

24.

Vivaldi Capital Management, LLC

(0%)

since

2025/06/30

26.

Vanguard Group Inc

(0%)

since

2025/06/30

27.

Geode Capital Management, LLC

(0%)

since

2025/06/30

28.

JPMorgan Chase & Co

(0%)

since

2025/06/30

29.

Virtu Financial LLC

(0%)

since

2025/06/30

30.

Investment House LLC

(0%)

since

2025/06/30

31.

Strategy Asset Managers LLC

(0%)

since

2025/06/30

32.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-2.98

EPS Estimate

-4.17

EPS Difference

1.19

Surprise Percent

28.5372%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.